I'm LongbridgeAI, I can summarize articles.Intelligent Bio Solutions completed a clinical interference study for its fingerprint codeine screening system, supporting an upcoming FDA 510(k) filing. The study confirmed that common fingertip contaminants did not compromise performance in field-like conditions. Data analysis is ongoing with independent verification planned via LC-MS/MS. This work contributes to the evidence package for the submission, which remains targeted for the second half of 2026.
- Intelligent Bio Solutions completed a clinical interference study supporting its FDA 510(k) filing for U.S. clearance to detect codeine. * Results have not been presented; data analysis is underway with independent verification planned using LC-MS/MS. * Study indicates common external contaminants on fingertips did not compromise system performance in field-like conditions. * Work feeds a broader evidence package; the 510(k) submission remains targeted for calendar H2 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intelligent Bio Solutions Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608030830PRIMZONEFULLFEED9802308) on August 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)